ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a mix of positive and negative factors. The merger and asset purchase agreements are strategic moves that could enhance shareholder value, but there are risks associated with integration and market adoption challenges. Financial performance shows modest revenue growth and improved margins, but overall sales have contracted. The Q&A session reveals uncertainties about product development and market competition from GLP-1s. Despite cost reductions, the lack of strong guidance and the uncertainty in market adoption balance the positives, suggesting a neutral sentiment with limited short-term stock price movement.
Key Financial Performance
Revenue (Q3 2024) $2.3 million, an increase of 6% or $100,000 compared to Q3 2023, primarily due to an increase in sales volume, offset by pressure from GLP-1 pharmaceutical weight loss alternatives.
Revenue (9 months 2024) $6.2 million, a contraction of 7% or $500,000 compared to the same period in 2023, primarily due to a decrease in sales volume from GLP-1 alternatives.
Gross Profit (Q3 2024) $1.4 million, slightly above $1.3 million for Q3 2023, with a gross profit margin of 63% compared to 60% in Q3 2023, due to reduction of overhead-related costs.
Gross Profit (9 months 2024) $3.7 million, unchanged compared to the same period in 2023, with a gross profit margin of 60% compared to 55% in 2023, attributed to reduced overhead costs.
Sales and Marketing Expenses (Q3 2024) $700,000, a decrease of $1.1 million or 60% compared to Q3 2023, primarily due to reduced advertising and marketing expenses and a shift to targeted digital marketing.
Sales and Marketing Expenses (9 months 2024) $2.4 million, a decrease of $3.7 million or 61% compared to the same period in 2023, due to reduced advertising, consulting, and payroll-related expenditures.
General Administrative Expenses (Q3 2024) Approximately $2.1 million, a slight increase of $45,000 or 1% compared to Q3 2023, due to increased professional services related to the merger, offset by reductions in employee-related expenses.
General Administrative Expenses (9 months 2024) $6.1 million, a decrease of $2.7 million or 30% compared to the same period in 2023, primarily due to reduced professional services and payroll-related expenses.
Research and Development Expenses (Q3 2024) $400,000, a decrease of $100,000 or 26% compared to Q3 2023, primarily due to reductions in payroll, consulting, and clinical trials.
Research and Development Expenses (9 months 2024) $1.3 million, a decrease of $300,000 or 19% compared to the same period in 2023, primarily due to reductions in payroll and consulting.
Non-GAAP Adjusted EBITDA (Q3 2024) $1.6 million, compared to a loss of $2.9 million in Q3 2023, an improvement of $1.2 million, due to continued efforts to reduce operating costs.
Non-GAAP Adjusted EBITDA (9 months 2024) Loss of $5.6 million, improved from a loss of $12 million in the same period last year, an improvement of $6.4 million, primarily due to reduced operating costs.
Net Working Capital (Q3 2024) $1.3 million, including cash and cash equivalents and restricted cash of $800,000.
Operating Highlights
Lap-Band 2.0 FLEX Launch: Commercial launch of the redesigned Lap-Band 2.0 FLEX has been initiated, with positive initial surgeon feedback and a patient-centric website receiving meaningful traffic.
NIH Grant for DBSN Device: Awarded approximately $241,000 supplementary grant from NIH for studies on next-generation electrodes for the proprietary Diabetes Bloc-Stim Neuromodulation device.
Market Expansion in Canada: Received approval for Lap-Band 2.0 FLEX from Health Canada, aiming for regulatory approvals worldwide.
Merger with Vyome Therapeutics: Merger with Vyome Therapeutics is expected to enhance market positioning and shareholder value.
Cost Reduction Plan: Achieved over 40% lower operating expenses for the first nine months of 2024 compared to last year.
Revenue Growth: Revenue increased by 16.6% in Q3 2024 over Q2 2024, marking the third sequential quarter of growth.
Merger and Asset Sale: Merger with Vyome and asset sale to Biorad for $5.16 million are strategic moves to maximize shareholder value.
Focus on Obesity Market: Plans to capitalize on the growing acceptance of medical interventions for obesity, particularly with the Lap-Band 2.0 FLEX.
Risk or Challenges
Competitive Pressures: The company faces competitive pressures from GLP-1 pharmaceutical weight loss alternatives, which have impacted sales volume and market share.
Regulatory Issues: The company is navigating regulatory approvals for its products, including the recent approval for the Lap-Band 2.0 FLEX from Health Canada.
Supply Chain Challenges: There are potential supply chain challenges related to the commercialization of the Lap-Band 2.0 FLEX and the overall production of medical devices.
Economic Factors: The economic burden associated with the adoption of GLP-1s may influence the market dynamics for bariatric surgeries and the demand for the company's products.
Merger Risks: The merger with Vyome Therapeutics presents risks related to integration, execution of the business strategy, and realization of anticipated synergies.
Market Adoption: There is uncertainty regarding the long-term adoption of the Lap-Band system as societal attitudes towards obesity treatment evolve.
Guidance & Outlook
Revenue Growth: Revenue increased 16.6% in Q3 2024 over Q2 2024, marking the third sequential quarter of growth.
Cost Reduction Plan: Executed a 2024 cost reduction plan leading to over 40% lower operating expenses for the first nine months of 2024 compared to last year.
Gross Profit Margin: Gross profit margin increased to 62.8% for Q3 2024 and 60.3% for the first nine months.
Lap-Band 2.0 FLEX Launch: Commercial launch of the redesigned Lap-Band 2.0 FLEX is underway, with positive initial feedback from surgeons.
NIH Grant: Received a $241,000 supplementary grant from NIH for studies on next-generation electrodes for the DBSN device.
Merger with Vyome Therapeutics: Merger with Vyome is expected to maximize shareholder value and earnings potential.
Asset Sale to Biorad: Asset purchase agreement with Biorad for $5.16 million to pay down costs associated with the Vyome transaction.
Future Revenue Expectations: Expect continued growth in revenue as the obesity market expands and more individuals seek medical intervention.
Financial Projections: Projected significant upside beyond the $130 million valuation of the combined entity post-merger with Vyome.
Market Opportunity: Anticipate increased demand for minimally invasive options like Lap-Band as societal stigma around obesity decreases.
Cost Management: Continued focus on disciplined cost management to enhance profitability and shareholder value.
Shareholder Return Plan
Asset Purchase Agreement with Biorad: ReShape Lifesciences has entered into an asset purchase agreement with Biorad for $5.16 million in cash, which will help pay down costs associated with the merger with Vyome Therapeutics.
Merger with Vyome Therapeutics: The merger with Vyome Therapeutics is expected to maximize stockholder value and earnings potential, with a combined company valuation of approximately $130 million.
Cost Reduction Plan: ReShape has implemented a cost reduction plan that has led to a 41% reduction in overall operating costs for the first nine months of 2024 compared to the same period last year.
NIH Grant: ReShape received a $241,000 supplementary grant from NIH, bringing total NIH awards to $1.15 million, supporting their Diabetes Bloc-Stim Neuromodulation device.
Key Q&A
Earnings Word Cloud
RSLS Transcript
The earnings call highlights a mix of positive and negative factors. The merger and asset purchase agreements are strategic moves that could enhance shareholder value, but there are risks associated with integration and market adoption challenges. Financial performance shows modest revenue growth and improved margins, but overall sales have contracted. The Q&A session reveals uncertainties about product development and market competition from GLP-1s. Despite cost reductions, the lack of strong guidance and the uncertainty in market adoption balance the positives, suggesting a neutral sentiment with limited short-term stock price movement.
The earnings call highlights a revenue decline due to competitive pressures, supply chain challenges, and regulatory risks, despite cost reductions. The merger and asset sales could enhance future growth, but immediate concerns overshadow these prospects. The Q&A lacks clarity, further adding uncertainty. Overall, the negative financial performance and risks outweigh the positive elements, leading to a likely negative stock price movement.
The earnings call reveals mixed signals. While cost reductions and a new partnership with Bio-Rad are positive, the decrease in revenue and gross profit due to GLP-1 drug competition is concerning. The Q&A section shows optimism about overcoming GLP-1 challenges, but management's lack of clarity on long-term impact and timelines tempers enthusiasm. The stock price is likely to remain stable in the short term, with minor fluctuations.
RSLS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
